Exercise and GLP-1 Medications (Semaglutide / Ozempic / Wegovy)
GLP-1 medications and exercise — what you need to know
GLP-1 receptor agonists — including semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management), tirzepatide (Mounjaro) and liraglutide (Victoza/Saxenda) — have transformed the management of type 2 diabetes and obesity, producing levels of weight loss that were previously only achievable through bariatric surgery. In Australia, these medications have moved rapidly from specialist prescribing to widespread GP-initiated use, and the number of people taking GLP-1 medications is growing rapidly across every demographic.
What is less widely understood — and critically important — is that GLP-1 medications produce weight loss that includes a significant proportion of lean muscle mass alongside fat mass. Without structured resistance exercise, a substantial portion of the weight lost on a GLP-1 medication will be muscle rather than fat — leaving the person lighter but weaker, with reduced metabolic capacity and a higher risk of functional decline, particularly in older adults. This is not a minor consideration. The preservation of lean muscle mass during GLP-1-induced weight loss is one of the most important determinants of long-term outcomes — and it requires deliberate, structured resistance training alongside the medication.
At Articulate Physiotherapy in Tarragindi, our Accredited Exercise Physiologist Ash O'Regan provides individually designed exercise programs for people taking GLP-1 medications — building and preserving lean muscle mass, improving metabolic health and supporting the long-term outcomes that medication alone cannot achieve.
What do GLP-1 medications do?
GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking the GLP-1 hormone that is naturally released after eating. They reduce appetite, slow gastric emptying, increase feelings of fullness and — at pharmacological doses — produce significant reductions in caloric intake that result in substantial weight loss. For people with type 2 diabetes they also improve blood glucose control through multiple mechanisms including stimulating insulin release and suppressing glucagon.
The weight loss produced by GLP-1 medications is genuine and clinically significant — trials of semaglutide (Wegovy) have shown average weight loss of 15 to 20% of body weight over 68 weeks, which is comparable to the outcomes of bariatric surgery for many patients. However the composition of that weight loss — how much is fat and how much is muscle — is heavily influenced by whether resistance exercise is performed alongside the medication.
The muscle mass problem
Studies of semaglutide and other GLP-1 medications consistently show that a significant proportion of the weight lost — typically 25 to 40% — is lean mass rather than fat mass when exercise is not specifically addressed. For a person losing 20 kilograms on a GLP-1 medication, this could mean losing 5 to 8 kilograms of muscle — a loss that is clinically significant, particularly for older adults whose muscle mass is already declining with age.
The consequences of muscle mass loss during GLP-1-induced weight loss include reduced resting metabolic rate — making weight regain more likely if the medication is stopped — reduced functional strength and physical capacity, increased falls risk in older adults, reduced bone density, and the loss of the metabolic benefits that muscle tissue provides including improved insulin sensitivity and glucose uptake.
Structured resistance exercise — performed consistently throughout the period of GLP-1-induced weight loss — is the most effective intervention for preserving lean muscle mass during the weight loss phase. It does not prevent the medication from working. It ensures that what is lost is predominantly fat rather than muscle.
Why exercise with a GLP-1 medication is different
Several factors make exercise prescription for people on GLP-1 medications genuinely different from standard exercise prescription — which is why working with an Accredited Exercise Physiologist rather than a personal trainer is the appropriate approach for this population.
Reduced appetite and energy intake. GLP-1 medications significantly reduce appetite and caloric intake. Exercising in a substantial caloric deficit — particularly high-intensity exercise — can produce excessive fatigue, poor recovery and dizziness. Exercise intensity, duration and timing relative to meals must be calibrated to the individual's current dietary intake and tolerance.
Nausea and gastrointestinal side effects. Nausea is the most common side effect of GLP-1 medications, particularly in the dose titration phase. Exercise timing relative to medication administration and meal timing significantly affects nausea tolerance during exercise, and the program must account for this practically.
Protein intake. Adequate protein intake is the nutritional co-intervention most important for muscle preservation during GLP-1-induced weight loss. Exercise physiology advice on protein timing and distribution — working alongside dietary guidance from a dietitian — is an important component of the program.
Cardiovascular considerations. For patients taking GLP-1 medications for type 2 diabetes or cardiovascular disease, exercise prescription must account for the cardiovascular effects of the medication and any co-existing cardiac conditions. Ash works collaboratively with your GP and specialist to ensure the exercise program is appropriate for your specific medical context.
Bone density. Weight loss of any cause — including GLP-1-induced weight loss — can reduce bone density. Resistance training and weight-bearing exercise are the primary evidence-based interventions for maintaining bone density during weight loss and are important components of the program for patients at risk of osteoporosis.
What does the exercise program involve?
The exercise program for people on GLP-1 medications is built around progressive resistance training — the primary intervention for muscle mass preservation — combined with aerobic exercise for cardiovascular health and metabolic benefit. The specific program is individualised based on the patient's current fitness level, medical history, GLP-1 dosing phase, dietary intake and goals.
Resistance training typically begins with two to three sessions per week targeting all major muscle groups — lower body, upper body and core — using a combination of machine-based, free weight and bodyweight exercises. The emphasis is on progressive overload — systematically increasing the challenge over time — which is the fundamental stimulus for muscle preservation and growth.
Aerobic exercise complements the resistance training by improving cardiovascular fitness, supporting metabolic health and contributing to the overall energy balance. Walking, cycling, swimming and low-impact cardiovascular activity are all appropriate and can be integrated around the resistance training program.
The program progresses systematically as the patient's capacity and tolerance improve — with regular reassessment to ensure the program remains appropriately challenging and aligned with the patient's current medication dosing and dietary intake.
Stopping GLP-1 medications — exercise is even more important
Clinical trials show that significant weight regain occurs when GLP-1 medications are stopped without accompanying lifestyle changes. The patients who maintain their weight loss most effectively after stopping GLP-1 medications are those who have developed sustainable exercise habits and preserved their lean muscle mass during the weight loss phase. This makes establishing a consistent exercise program during the medication period — not after it — the most important timing for exercise intervention.
Funding pathways
Exercise physiology for people taking GLP-1 medications for type 2 diabetes or obesity-related chronic conditions may be accessible through a GP Chronic Condition Management Plan (GPCCMP) — five Medicare-subsidised sessions per calendar year at $61.80 rebate per session. Private health insurance may also cover exercise physiology sessions depending on your fund and level of cover.
Our Accredited Exercise Physiologist Ash O'Regan holds a Bachelor of Clinical Exercise Physiology from QUT and is a member of Exercise and Sports Science Australia (ESSA). She works collaboratively with your GP and other treating practitioners to ensure your exercise program is coordinated with your GLP-1 medication management plan.
To book or find out more, call us on 07 3706 3407 or book online below. We see patients from across Brisbane's southside including Tarragindi, Coorparoo, Holland Park, Greenslopes and Mt Gravatt.
GLP-1 receptor agonists — including semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management), tirzepatide (Mounjaro) and liraglutide (Victoza/Saxenda) — have transformed the management of type 2 diabetes and obesity, producing levels of weight loss that were previously only achievable through bariatric surgery. In Australia, these medications have moved rapidly from specialist prescribing to widespread GP-initiated use, and the number of people taking GLP-1 medications is growing rapidly across every demographic.
What is less widely understood — and critically important — is that GLP-1 medications produce weight loss that includes a significant proportion of lean muscle mass alongside fat mass. Without structured resistance exercise, a substantial portion of the weight lost on a GLP-1 medication will be muscle rather than fat — leaving the person lighter but weaker, with reduced metabolic capacity and a higher risk of functional decline, particularly in older adults. This is not a minor consideration. The preservation of lean muscle mass during GLP-1-induced weight loss is one of the most important determinants of long-term outcomes — and it requires deliberate, structured resistance training alongside the medication.
At Articulate Physiotherapy in Tarragindi, our Accredited Exercise Physiologist Ash O'Regan provides individually designed exercise programs for people taking GLP-1 medications — building and preserving lean muscle mass, improving metabolic health and supporting the long-term outcomes that medication alone cannot achieve.
What do GLP-1 medications do?
GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking the GLP-1 hormone that is naturally released after eating. They reduce appetite, slow gastric emptying, increase feelings of fullness and — at pharmacological doses — produce significant reductions in caloric intake that result in substantial weight loss. For people with type 2 diabetes they also improve blood glucose control through multiple mechanisms including stimulating insulin release and suppressing glucagon.
The weight loss produced by GLP-1 medications is genuine and clinically significant — trials of semaglutide (Wegovy) have shown average weight loss of 15 to 20% of body weight over 68 weeks, which is comparable to the outcomes of bariatric surgery for many patients. However the composition of that weight loss — how much is fat and how much is muscle — is heavily influenced by whether resistance exercise is performed alongside the medication.
The muscle mass problem
Studies of semaglutide and other GLP-1 medications consistently show that a significant proportion of the weight lost — typically 25 to 40% — is lean mass rather than fat mass when exercise is not specifically addressed. For a person losing 20 kilograms on a GLP-1 medication, this could mean losing 5 to 8 kilograms of muscle — a loss that is clinically significant, particularly for older adults whose muscle mass is already declining with age.
The consequences of muscle mass loss during GLP-1-induced weight loss include reduced resting metabolic rate — making weight regain more likely if the medication is stopped — reduced functional strength and physical capacity, increased falls risk in older adults, reduced bone density, and the loss of the metabolic benefits that muscle tissue provides including improved insulin sensitivity and glucose uptake.
Structured resistance exercise — performed consistently throughout the period of GLP-1-induced weight loss — is the most effective intervention for preserving lean muscle mass during the weight loss phase. It does not prevent the medication from working. It ensures that what is lost is predominantly fat rather than muscle.
Why exercise with a GLP-1 medication is different
Several factors make exercise prescription for people on GLP-1 medications genuinely different from standard exercise prescription — which is why working with an Accredited Exercise Physiologist rather than a personal trainer is the appropriate approach for this population.
Reduced appetite and energy intake. GLP-1 medications significantly reduce appetite and caloric intake. Exercising in a substantial caloric deficit — particularly high-intensity exercise — can produce excessive fatigue, poor recovery and dizziness. Exercise intensity, duration and timing relative to meals must be calibrated to the individual's current dietary intake and tolerance.
Nausea and gastrointestinal side effects. Nausea is the most common side effect of GLP-1 medications, particularly in the dose titration phase. Exercise timing relative to medication administration and meal timing significantly affects nausea tolerance during exercise, and the program must account for this practically.
Protein intake. Adequate protein intake is the nutritional co-intervention most important for muscle preservation during GLP-1-induced weight loss. Exercise physiology advice on protein timing and distribution — working alongside dietary guidance from a dietitian — is an important component of the program.
Cardiovascular considerations. For patients taking GLP-1 medications for type 2 diabetes or cardiovascular disease, exercise prescription must account for the cardiovascular effects of the medication and any co-existing cardiac conditions. Ash works collaboratively with your GP and specialist to ensure the exercise program is appropriate for your specific medical context.
Bone density. Weight loss of any cause — including GLP-1-induced weight loss — can reduce bone density. Resistance training and weight-bearing exercise are the primary evidence-based interventions for maintaining bone density during weight loss and are important components of the program for patients at risk of osteoporosis.
What does the exercise program involve?
The exercise program for people on GLP-1 medications is built around progressive resistance training — the primary intervention for muscle mass preservation — combined with aerobic exercise for cardiovascular health and metabolic benefit. The specific program is individualised based on the patient's current fitness level, medical history, GLP-1 dosing phase, dietary intake and goals.
Resistance training typically begins with two to three sessions per week targeting all major muscle groups — lower body, upper body and core — using a combination of machine-based, free weight and bodyweight exercises. The emphasis is on progressive overload — systematically increasing the challenge over time — which is the fundamental stimulus for muscle preservation and growth.
Aerobic exercise complements the resistance training by improving cardiovascular fitness, supporting metabolic health and contributing to the overall energy balance. Walking, cycling, swimming and low-impact cardiovascular activity are all appropriate and can be integrated around the resistance training program.
The program progresses systematically as the patient's capacity and tolerance improve — with regular reassessment to ensure the program remains appropriately challenging and aligned with the patient's current medication dosing and dietary intake.
Stopping GLP-1 medications — exercise is even more important
Clinical trials show that significant weight regain occurs when GLP-1 medications are stopped without accompanying lifestyle changes. The patients who maintain their weight loss most effectively after stopping GLP-1 medications are those who have developed sustainable exercise habits and preserved their lean muscle mass during the weight loss phase. This makes establishing a consistent exercise program during the medication period — not after it — the most important timing for exercise intervention.
Funding pathways
Exercise physiology for people taking GLP-1 medications for type 2 diabetes or obesity-related chronic conditions may be accessible through a GP Chronic Condition Management Plan (GPCCMP) — five Medicare-subsidised sessions per calendar year at $61.80 rebate per session. Private health insurance may also cover exercise physiology sessions depending on your fund and level of cover.
Our Accredited Exercise Physiologist Ash O'Regan holds a Bachelor of Clinical Exercise Physiology from QUT and is a member of Exercise and Sports Science Australia (ESSA). She works collaboratively with your GP and other treating practitioners to ensure your exercise program is coordinated with your GLP-1 medication management plan.
To book or find out more, call us on 07 3706 3407 or book online below. We see patients from across Brisbane's southside including Tarragindi, Coorparoo, Holland Park, Greenslopes and Mt Gravatt.
Who to book in with:
If you are unsure about which appointment type is right for you, please don't hesitate to get in touch with our friendly reception staff by calling 07 3706 3407 or emailing [email protected].